Infigratinib Reduces Fibroblast Growth Factor 23 (FGF23) and Increases Blood Phosphate in Tumor‐Induced Osteomalacia

Infigratinib Reduces Fibroblast Growth Factor 23 (FGF23) and Increases Blood Phosphate in Tumor‐Induced Osteomalacia

ABSTRACT Tumor‐induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by ectopic production of fibroblast growth factor 23 (FGF23) by phosphaturic mesenchymal tumors (PMTs). Acting on renal tubule cells, excess FGF23 decreases phosphate reabsorption and 1,25‐dihydroxy‐vitamin D (1,25D)...

Full description

Bibliographic Details
Main Authors: Iris R. Hartley, Kelly L. Roszko, Xiaobai Li, Karen Pozo, Jamie Streit, Jaydira delRivero, M. Teresa Magone, Michaele R. Smith, Roo Vold, Carl L. Dambkowski, Michael T. Collins, Rachel I. Gafni
Format: Article
Language:English
Published: Wiley 2022-08-01
Series:JBMR Plus
Subjects:
OSTEOMALACIA AND RICKETS
CLINICAL TRIALS
TUMOR‐INDUCED BONE DISEASE
THERAPEUTICS: OTHER
DISORDERS OF CALCIUM/PHOSPHATE METABOLISM: OTHER
Online Access:https://doi.org/10.1002/jbm4.10661

Internet

https://doi.org/10.1002/jbm4.10661

Similar Items